导师介绍

分子医学博士生导师蔡佩娥介绍

个人简介:

博士,医学研究中心研究员。博士生导师。主要从事纳米技术生物医用材料研究。

个人简历:

2005/8-2008/8  马来西亚大学沙巴州分校  学士

2009/3-2014/2  韩国先进科学技术研究院  博士

2014.2-2015.5  韩国先进科学技术研究院  博士后 

2015.5-2018.3  美国哈佛大学医学院  博士后

2018.3-至今  中山大学孙逸仙纪念医院  研究员

 
科研工作:

研究领域

1.  纳米载体的构建及其性能评价

2. 脂质体纳米载体用于小分子抗肿瘤药物靶向输送和肿瘤治疗

3.  纳米载体用于大分子蛋白质靶向输送和疾病治疗

4. 刺激-响应型纳米载体用于RNA的靶向输送和肿瘤治疗 

参与科研项目

1.  Prostate Cancer Foundation    $5644,124  2007-2014

  Nanotechnology for treatment of prostate cancer  骨干 

2.  NIH EB015419-01    $2562,165  2012-2017

  Development of FcRn-targeted nanoparticles for efficient oral delivery of insulin  参与

3.  National Science Foundation Youth Award 2018 (RMB 220,000) 

4.  High-level Talent Special Funding Scheme of Sun Yat-Sen Memorial Hospital (RMB 3,000,000)

 

著作、论文、成果:

论文发表

1. Saw PE, Song E. Phage Display Technique for Tumor-targeting High Affinity Peptide Identification. Protein & Cell. 2019 May 28. doi: 10.1007/s13238-019-0639-7. [Epub ahead of print] (影响因子:6.228)

2. Saw PE, Lee SY, Jon S. Naturally occurring bioactive compound-derived nanoparticles for biomedical applications. Advanced Therapeutics, Vol 2, Issue 5. https://doi.org/10.1002/adtp.201800146 (影响因子:- )

3. Saw PE, Song E. siRNA therapeutics: A clinical reality. Sci China Life Sci. 2019 Apr 30. doi: 10.1007/s11427-018-9438-y. [Epub ahead of print]. (影响因子: 3.085)

4. Nie Y, Huang H, Guo M, Chen J, Wu W, Li W, Xu X, Lin X, Fu W, Yao Y, Zheng F, Luo ML, Saw PE, Yao H, Song E, Hu H. Breast Phyllodes Tumors Recruit and Repolarize Tumor-Associated Macrophages via Secreting CCL5 to Promote Malignant Progression, Which Can Be Inhibited by CCR5 Inhibition Therapy. Clin Cancer Res. 2019 Mar 19. doi: 10.1158/1078-0432.CCR-18-3421. [Epub ahead of print] (影响因子: 10.199)

5. Yao Y*, Saw PE*, Nie Y, Wong P, Jiang L, Ye X, Chen J, Ding T, Xu L, Yao H, Hu H and X Xu. Multifunctional sharp pH-responsive nanoparticles for targeted drug delivery and effective breast cancer therapy. J. Mater. Chem. B, 2018, 00, 1-10 (* co-first author) (影响因子: 4.543)

6. Saw PE, Zhang A, Nie Y, Zhang L, Xu Y, Xu X. Tumor-Associated Fibronectin Targeted Liposomal Nanoplatform for Cyclophilin A siRNA Delivery and Targeted Malignant Glioblastoma Therapy. Front Pharmacol. 2018 Oct 17;9:1194. (影响因子: 3.831)

7. Liang S, Zheng J, Wu W, Li Q, Saw PE, Chen J, Xu X, Yao H, Yao Y. A Robust Nanoparticle Platform for RNA Interference in Macrophages to Suppress Tumor Cell Migration. Front Pharmacol. 2018 Dec 14;9:1465. (影响因子: 3.831)

8. Xu X, Wu J, Liu S, Saw PE, Tao W, Li Y, Krygsman L, Yegnasubramanian S, De Marzo AM, Shi J, Bieberich CJ, Farokhzad OC. Redox-Responsive Nanoparticle-Mediated Systemic RNAi for Effective Cancer Therapy. Small. 2018 Oct;14(41):e1802565 (影响因子: 8.598)

9. Tao W, Ji X , Zhu X, Li L, Wang J, Zhang Y, Saw PE, Li W Li, Kong N, Islam MA, Gan T, Zeng X, Zhang H, Mahmoudi M, Tearney GJ, Farokhzad OC. Two‐Dimensional Antimonene‐Based Photonic Nanomedicine for Cancer Theranostics. Adv Mater. 2018 Sep;30(38):e1802061 (影响因子: 21.95)

10. Li E, Cheng X, Deng Y, Zhu J, Xu X, Saw PE, Gu H, Ge C, Pan Y: Fabrication of PEGylated Fe@Bi2S3 Nanocomposites for Dual-mode Imaging and Synergistic Thermoradiotherapy. J Biomater Sci 2018 May; 6(7).  (影响因子: 5.831)

11. Yu M, Amengual J, Menon A, Kamaly N, Zhou F, Xu X, Saw PE, Lee SJ, Si K, Ortega CA, Choi WI, Lee IH, Bdour Y, Shi J, Mahmoudi M, Jon S, Fisher EA, Farokhzad OC. Targeted Nanotherapeutics Encapsulating Liver X Receptor Agonist GW3965 Enhance Antiatherogenic Effects without Adverse Effects on Hepatic Lipid Metabolism in Ldlr-/- Mice. Adv Healthc Mater. 2017 Oct;6(20) (影响因子: 5.609)

12. Tao W, Ji X, Xu X, Islam MA, Li Z, Chen S, Saw PE, Zhang H, Bharwani Z, Guo Z, Shi J, Farokhzad OC. Antimonene Quantum Dots: Synthesis and Application as Near-Infrared Photothermal Agents for Effective Cancer Therapy. Angew Chem Int Ed Engl. 2017 Sep 18;56(39):11896-11900 (影响因子: 12.102)

13. Xu X*, Saw PE*, Tao W, Li Y, Ji X, Bhasin S, Liu Y, Ayyash D, Rasmussen J, Huo M, Shi J, Farokhzad OC. ROS-Responsive Polyprodrug Nanoparticles for Triggered Drug Delivery and Effective Cancer Therapy. Adv Mater. 2017 Sep;29(33) *co-first author (影响因子: 21.95)

14. Xu X, Saw PE, Tao W, Li Y, Ji X, Yu M, Mahmoudi M, Rasmussen J, Ayyash D, Zhou Y, Farokhzad OC, Shi J. Tumor Microenvironment-Responsive Multistaged Nanoplatform for Systemic RNAi and Cancer Therapy. Nano Lett. 2017 Jul 12;17(7):4427-4435. (影响因子: 12.08)

15. Saw PE, Yu M, Choi M, Lee E, Jon S, Farokhzad OC. Hyper-cell-permeable micelles as a drug delivery carrier for effective cancer therapy. Biomaterials. 2017 Apr;123:118-126 (影响因子: 8.806)

16. Xu X, Wu J, Liu Y, Saw PE, Tao W, Yu M, Zope H, Si M, Victorious A, Rasmussen J, Ayyash D, Farokhzad OC, Shi J. Multifunctional Envelope-Type siRNA Delivery Nanoparticle Platform for Prostate Cancer Therapy. ACS Nano. 2017 Mar 28;11(3):2618-2627(影响因子: 13.709)

17. Saw PE, Park J, Jon S, Farokhzad OC. A drug-delivery strategy for overcoming drug resistance in breast cancer through targeting of oncofetal fibronectin. Nanomedicine. 2017 Feb;13(2):713-722 (影响因子: 6.35)

18. Choi M, Lee SH, Kim WB, Gujrati V, Kim D, Lee J, Kim JI, Kim H, Saw PE, Jon S. Intracellular Delivery of Bioactive Cargos to Hard-to-Transfect Cells Using Carbon Nanosyringe Arrays under an Applied Centrifugal g-Force. Adv Healthc Mater. 2016 Jan 7;5(1):101-7 (影响因子: 5.609)

19. Lee J, Saw PE, Gujrati V, Lee Y, Kim H, Kang S, Choi M, Kim JI, Jon S. Mono-arginine Cholesterol-based Small Lipid Nanoparticles as a Systemic siRNA Delivery Platform for Effective Cancer Therapy. Theranostics. 2016 Jan 1;6(2):192-203. (影响因子: 8.537)

20. Sun Y*, Kim HS*, Saw PE*, Jon S, Moon WK. Targeted Therapy for Breast Cancer Stem Cells by Liposomal Delivery of siRNA against Fibronectin EDB. Adv Healthc Mater. 2015 Aug 5;4(11):1675-80 *co-first author (影响因子: 5.609)

21. Saw PE, Park J, Lee E, Ahn S, Lee J, Kim H, Kim J, Choi M, Farokhzad OC, Jon S. Effect of PEG pairing on the efficiency of cancer-targeting liposomes. Theranostics. 2015 Apr 5;5(7):746-54 (影响因子: 8.537)

22. Choi M, Lee SH, Kim WB, Gujrati V, Kim D, Lee J, Kim J, Kim H, Saw PE, Jon S. Intracellular Delivery of Bioactive Cargos to Hard-to-Transfect Cells Using Carbon Nanosyringe Arrays under an Applied Centrifugal g-Force. Advanced Healthcare Materials 2015; 5(1); 101-7. (影响因子: 5.609)

23. Ahn S, Lee IH, Kang S, Kim D, Choi M, Saw PE, Shin EC, Jon S. Gold nanoparticles displaying tumor-associated self-antigens as a potential vaccine for cancer immunotherapy. Adv Healthc Mater. 2014 Aug;3(8):1194-9 (影响因子: 5.609)

24. Kim D, Lee IH, Kim S, Choi M, Kim H, Ahn S, Saw PE, Jeon H, Lee Y, Jon S. A specific STAT3-binding peptide exerts antiproliferative effects and antitumor activity by inhibiting STAT3 phosphorylation and signaling. Cancer Res. 2014 Apr 15;74(8):2144-51 (影响因子: 9.13)

25. Kim H, Lee Y, Lee IH, Kim S, Kim D, Saw PE, Lee J, Choi M, Kim YC, Jon S. Synthesis and therapeutic evaluation of an aptide-docetaxel conjugate targeting tumor-associated fibronectin. J Control Release. 2014 Mar 28;178:118-24 (影响因子: 7.877)

26. Kim C, Yang H, Fukushima Y, Saw PE, Lee J, Park JS, Park I, Jung J, Kataoka H, Lee D, Heo WD, Kim I, Jon S, Adams RH, Nishikawa S, Uemura A, Koh GY. Vascular RhoJ is an effective and selective target for tumor angiogenesis and vascular disruption. Cancer Cell. 2014 Jan 13;25(1):102-17 (影响因子: 22.844)

27. Chong K, Ku T, Saw PE, Jon S, Park JH, Choi C. Enhancement of the photocytotoxic efficiency of sub-12 nm therapeutic polymeric micelles with increased co-localisation in mitochondria. Chem Commun (Camb). 2013 Dec 21;49(98):11476-8 (影响因子: 6.319)

 

授权/受理专利

1. Sangyong Jon, Sunghyun Kim, Seho Park, Daejin Kim, Jinho Park, Saw Phei Er, “Bipodal Peptide Binders-Based Cargo Delivery System”. 国际专利 PCT/KR2010/008645. (授权时间: 2010/12/3)

2. Sangyong Jon, Sunghyun Kim, Saw Phei Er, “T-cell specific aptides and their construction methods”. 韩国专利 2011-0145658 (授权时间: 2011/12/29)

3. Sangyong Jon, Young Tag Ko, Saw Phei Er “Gene Delivery system”.  韩国专利 10-1229809 (授权时间: 2013/1/30)

 

学术会议

1. IBN conference, A-Star, Singapore 2013. Aptide conjugated liposomal system for cancer therapy. (墙报)

2. CRS conference, Chicago (July, 2014). Variation of PEG length and its effect on the targeting efficacy of APTEDB-liposome in vitro and in vivo. (墙报)

3. Department of Anesthesia Research Day (October 2014). HCPMi as an efficient nanocarrier for cancer therapy. (墙报)

4. US-Japan Drug Delivery Symposium (December 2015). Nanoparticle encapsulated small molecule drug conjugate (SMDCs) as multi-staged targeting platform for efficient drug delivery. (墙报)

5. Osaka-KAIST symposium 2013. Aptide conjugated liposomal system for cancer therapy. (口头报告)

6. KAIST BK21 symposium 2014. Aptide conjugated liposomal system for cancer therapy. (口头报告)

Invited talk 

1. University Malaysia Sabah, UMS Biotechnology Alumni Talk Series 2016. Lipid-based Nanomedicine for Cancer Therapy. (口头报告)

2. University of Curtin, Malaysia Campus, Department of Chemical Engineering 2016. Lipid-based Nanomedicine for Cancer Therapy (口头报告)

3. Gwangju Institute of Science and Technology, Faculty of Life Sciences 2016. Lipid-based Nanomedicine for Cancer Therapy (口头报告)

4. Korea Advanced Institute of Science and Technology, Department of Biological Sciences 2016. Lipid-based Nanomedicine for Cancer Therapy (口头报告)

5. Korea University Guro Hospital, Department of Onco-neurological Surgery 2016. Lipid-based Nanomedicine for Cancer Therapy (口头报告)

6. Shunde Nanfang Medical School First Affiliated University 2018. Lipid-based Nanomedicine: Past, Present and Future (口头报告)

7. CCS Chemistry Spotlight Symposium, AsiaNANO2018. Lipid-based Nanomedicine: Past, Present and Future (口头报告)

8. UNIST-Sun Yat-sen Memorial Hospital Joint Symposium 2018.  Lipid-based Nanomedicine: Past, Present and Future (口头报告)

9. International Drug Delivery Symposium (IDDST), Osaka, Japan 2019. Lipid-based and Tumor-microenvironment Responsive Nanomedicine for Effective Cancer Therapy. (口头报告)

10. Nano S&T Conference, Suzhou, China 2019. Lipid-based and Tumor-microenvironment Responsive Nanomedicine for Effective Cancer Therapy. (口头报告)

 

获奖

1. Korean Government Scholarship for graduate students 2009-2014 

2. Best graduate student award 2009, 2010

3. Best oral presenter award at KAIST BK21 symposium 2014

4. Recipient of Brigham and Women’s Hospital Micro-grant Award 2016 

5. Top 4 most cited publication in the field of radio-oncology in South Korea 2016

6. Recipient of Metavivor Metastatic Breast Cancer Fellowship 2017 (USD 50000) 

 
更新时间:2019年08月07日

相关文章

  • 中山大学孙逸仙纪念医院研究生科

    电话:020-81332468,传真:020-81332608

    邮箱:graduate2@163.com

    地址:广州市沿江西路107号中山大学孙逸仙纪念医院中山楼703室

    办公时间:周一到周五 上午8:00-12:00,下午2:30-5:30